stockrowVericel Corporation
VCEL Healthcare Biotechnology
Vericel Corporation’s revenue for fiscal 2025 (year ended December 2025) was $276.3 million, up 16.5% from fiscal 2024.
- Revenue
- +26.5%
- EPS
- +180.0%
- Free cash flow
- −19.4%
Quarter to September 2026, against a year earlier
Follow VCEL
Alert me
Vericel Corporation (VCEL) Operating cash flow
Vericel Corporation's operating cash flow for fiscal 2025 was $51.9M, down 10.8% from $58.2M in fiscal 2024. Over the twelve months to 30 September 2026 it was $65.3M. Over the past ten years it has ranged from −$19.9M (fiscal 2016) to $58.2M (fiscal 2024); the current reading is higher than 91% of that period. Vericel Corporation ranks 33rd of 603 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | $51.9M | (10.75%) |
| FY2024 | $58.2M | 64.72% |
| FY2023 | $35.3M | 99.64% |
| FY2022 | $17.7M | (39.09%) |
| FY2021 | $29.0M | 65.26% |
| FY2020 | $17.6M | — |
| FY2019 | −$7.2M | — |
| FY2018 | −$412.0K | — |
| FY2017 | −$13.2M | — |
| FY2016 | −$19.9M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Sep 2026 | $17.7M | 9.46% |
| Jun 2026 | $16.2M | (1.17%) |
| Mar 2026 | $16.4M | 9.12% |
| Dec 2025 | $15.0M | (32.01%) |
| 43 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| AUPH Aurinia Pharmaceuticals Inc compare | $177.2M |
| ADMA ADMA Biologics Inc compare | $140.8M |
| VCEL Vericel Corporation | $65.3M |
| PVLA Palvella Therapeutics, Inc. compare | −$36.5M |
| PHVS Pharvaris N.V. compare | −$178.0M |
| IMNM Immunome, Inc. compare | −$208.8M |
| CLDX Celldex Therapeutics, Inc. compare | −$235.6M |
| VERA Vera Therapeutics, Inc. compare | −$338.7M |
| BHVN Biohaven Ltd. compare | −$472.5M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on VCEL
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement